Report of Foreign Issuer (6-k)

Date : 10/11/2019 @ 6:32PM
Source : Edgar (US Regulatory)
Stock : GlaxoSmithKline PLC (GSK)
Quote : 37.6  1.16 (3.18%) @ 11:45PM
After Hours
Last Trade
Last $ 37.60 ◊ 0.00 (0.00%)

Report of Foreign Issuer (6-k)

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of October 2019
 
Commission File Number 001-15170
 
 
GlaxoSmithKline plc
(Translation of registrant's name into English)
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
 
 
 
GlaxoSmithKline plc (the 'Company')
 
Transaction notification
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Ms E Walmsley
 
b)
Position/status
Chief Executive Officer
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GlaxoSmithKline plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2019, on shares held through the Company's Share Reward Plan.
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£17.1842
18
 
 
 
 
 
d)
Aggregated information
 
n/a (single transaction)
 
 
Aggregated volume Price
 
 
e)
Date of the transaction
2019-10-10
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Mr R Connor
 
b)
Position/status
President, Global Vaccines
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GlaxoSmithKline plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2019, on shares held through the Company's Share Reward Plan.
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£17.1842
61
 
 
 
 
 
d)
Aggregated information
 
n/a (single transaction)
 
 
Aggregated volume Price
 
 
e)
Date of the transaction
2019-10-10
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Mr N Hirons
 
b)
Position/status
SVP, Global Ethics & Compliance
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GlaxoSmithKline plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2019, on shares held through the Company's Share Reward Plan.
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£17.1842
12
 
 
 
 
 
d)
Aggregated information
 
n/a (single transaction)
 
 
Aggregated volume Price
 
 
e)
Date of the transaction
2019-10-10
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Ms S Jackson
 
b)
Position/status
SVP, Global Communications and CEO Office
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GlaxoSmithKline plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2019, on shares held through the Company's Share Reward Plan.
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£17.1842
56
 
 
 
 
 
d)
Aggregated information
 
n/a (single transaction)
 
 
Aggregated volume Price
 
 
e)
Date of the transaction
2019-10-10
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Mr D Jackson
 
b)
Position/status
PCA of Mrs S Jackson (SVP, Global Communications and CEO Office)
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GlaxoSmithKline plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2019, on shares held through the Company's Share Reward Plan.
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£17.1842
19
 
 
 
 
 
d)
Aggregated information
 
n/a (single transaction)
 
 
Aggregated volume Price
 
 
e)
Date of the transaction
2019-10-10
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Mr L Miels
 
b)
Position/status
President, Global Pharmaceuticals
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GlaxoSmithKline plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2019, on shares held through the Company's Share Reward Plan.
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£17.1842
3
 
 
 
 
 
d)
Aggregated information
 
n/a (single transaction)
 
 
Aggregated volume Price
 
 
e)
Date of the transaction
2019-10-10
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Mr D Redfern
 
b)
Position/status
Chief Strategy Officer
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GlaxoSmithKline plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2019, on shares held through the Company's Share Reward Plan.
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£17.1842
69
 
 
 
 
 
d)
Aggregated information
 
n/a (single transaction)
 
 
Aggregated volume Price
 
 
e)
Date of the transaction
2019-10-10
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Mr R Simard
 
b)
Position/status
President, Pharmaceuticals Supply Chain
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GlaxoSmithKline plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2019, on shares held through the Company's Share Reward Plan.
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£17.1842
18
 
 
 
 
 
d)
Aggregated information
 
n/a (single transaction)
 
 
Aggregated volume Price
 
 
e)
Date of the transaction
2019-10-10
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Mr P C Thomson
 
b)
Position/status
President, Global Affairs
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GlaxoSmithKline plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2019, on shares held through the Company's Share Reward Plan.
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£17.1842
39
 
 
 
 
 
d)
Aggregated information
 
n/a (single transaction)
 
 
Aggregated volume Price
 
 
e)
Date of the transaction
2019-10-10
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Ms V A Whyte
 
b)
Position/status
Company Secretary
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GlaxoSmithKline plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2019, on shares held through the Company's Share Reward Plan.
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£17.1842
50
 
 
 
 
 
d)
Aggregated information
 
n/a (single transaction)
 
 
Aggregated volume Price
 
 
e)
Date of the transaction
2019-10-10
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GlaxoSmithKline plc
 
(Registrant)
 
 
Date: October 11, 2019 
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GlaxoSmithKline plc
 
 
 

GlaxoSmithKline (NYSE:GSK)
Historical Stock Chart

1 Year : From Mar 2019 to Mar 2020

Click Here for more GlaxoSmithKline Charts.

GlaxoSmithKline (NYSE:GSK)
Intraday Stock Chart

Today : Monday 30 March 2020

Click Here for more GlaxoSmithKline Charts.

Latest GSK Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


$
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.